Kolesterol Metabolizması Bozuklukları
Özet
Kolesterol biyosentezi, hücre yapısı ve sinyal yolları için kritik olup, bu süreçteki enzim eksiklikleri çeşitli metabolik bozukluklara yol açmaktadır. Genetik mutasyonlar sonucu ortaya çıkan bu klinik tablolar, kolesterol eksikliği veya toksik ara metabolitlerin birikimi ile karakterize olup, geniş bir fenotipik yelpazede çoklu organ tutulumu ve psikomotor gerilikle prezente olurlar. Tanı genellikle biyokimyasal analizler ve moleküler genetik testlerle konulurken, tedavi yaklaşımı multidisipliner bir destek ve semptomatik müdahaleyi gerektirmektedir.
Cholesterol biosynthesis is critical for cellular structure and signaling pathways, and enzyme defects in this process lead to various complex metabolic disorders. These clinically distinct conditions arise from genetic mutations causing either cholesterol deficiency or the accumulation of toxic intermediate metabolites, often presenting with multiple congenital abnormalities and developmental delays. Diagnosis is primarily achieved through biochemical and molecular genetic testing, while management involves multidisciplinary supportive care and symptom-specific therapeutic strategies.
Referanslar
Waterham HR. Defects of cholesterol biosynthesis. FEBS Letters. 2006 Oct 9;580:5442–9.
Cooper MK, Wassif CA, Krakowiak PA, et al. A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat Genet. 2003 Apr;33(4):508–13.
Porter FD, Herman GE. Malformation syndromes caused by disorders of cholesterol synthesis. J Lipid Res. 2011 Jan;52(1):6-34.
Waterham HR, Clayton PT. Inborn Metabolic Diseases. Saudubray J-M, Baumgartner MR, Walter J, editors. 6th ed. Berlin, Heidelberg: Springer; 2016;455-63.
Anderson E, Coman D. Human Cholesterol Biosynthesis Defects. In: Waisundara, VY, Jovandaric MZ, editors. Apolipoproteins, Triglycerides and Cholesterol. London: IntechOpen; 2019 Jun.
Favier LA, Schulert GS. Mevalonate kinase deficiency: Current perspectives. Appl Clin Genet. 2016 Jul 20;9:101-10.
Jeyaratnam J, Frenkel J. Management of Mevalonate Kinase Deficiency: A Pediatric Perspective. Front. Immunol. 2020 Jun 5;11:1150.
Haas D, Hoffmann GF. Mevalonate kinase deficiencies: From mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet Journal of Rare Diseases. 2006 Feb;1:1-5.
Coman D, Vissers L, Waterham H, et al. Squalene Synthase Deficiency: Clinical, Biochemical, and Molecular Characterization of a Defect in Cholesterol Biosynthesis. Am J Hum Genet. 2018 Jul 5;103(1):125–30.
Coman D, Vissers L, Waterham H, et al. Squalene Synthase Deficiency. In: GeneReviews®. University of Washington, Seattle, Seattle (WA);1993. [Updated 2020 Feb 7].
OMIM Clinical Synopsis Table - #618840, #616509, #618275 Available from: https://www.omim.org/clinicalSynopsis/tableomimNumber=618840,616509,618275.
Thompson E, Abdalla E, Superti-Furga A, et al. Lamin B receptor-related disorder is associated with a spectrum of skeletal dysplasia phenotypes. Bone. 2019 Mar;120:354–63.
Gregersen PA, McKay V, Walsh M, Brown E, McGillivray G, Savarirayan R. A new case of Greenberg dysplasia and literature review suggest that Greenberg dysplasia, dappled diaphyseal dysplasia, and Astley–Kendall dysplasia are allelic disorders. Mol Genet Genomic Med. 2020 Jun;8(6):e1173.
Kalay Yildizhan I, Gökplnar İli E, Onoufriadis A, et al. New Homozygous Missense MSMO1 Mutation in Two Siblings with SC4MOL Deficiency Presenting with Psoriasiform Dermatitis. Cytogenet Genome Res. 2020 Nov;160:523-30.
Ramphul K, Kota V, Mejias SG. Child Syndrome. In: StatPearls. Treasure Island (FL), StatPearls Publishing; 2021 Jan.
du Souich C, Raymond FL, Grzeschik KH, Boerkoel CF. NSDHL-Related Disorders. In: GeneReviews®. University of Washington, Seattle, Seattle (WA);1993. [Updated 2018 Oct 25].
Herman GE, Kratz L. Disorders of sterol synthesis: Beyond Smith-Lemli-Opitz syndrome. Am J Med Genet Part C Semin Med Genet. 2012 Nov 15;160 C(4):301–21.
Kumble S, Savarirayan R. Chondrodysplasia Punctata 2, X-Linked. In: GeneReviews®. University of Washington, Seattle, Seattle (WA);1993-2021 [Updated 2020 Jan 9].
Yaplito-Lee J, Pai G, Hardikar W, et al. Successful treatment of lathosterolosis: A rare defect in cholesterol biosynthesis—A case report and review of literature. JIMD Rep. 2020 Nov;56(1):14–9.
Calvo PL, Brunati A, Spada M, et al. Liver transplantation in defects of cholesterol biosynthesis: the case of lathosterolosis. Am J Transplant. 2014 Apr;14(4):960-5.
Dias C, Rupps R, Millar B, et al. Desmosterolosis: an illustration of diagnostic ambiguity of cholesterol synthesis disorders. Orphanet J Rare Dis. 2014 Jun;9(1):1-6.
Rohanizadegan M, Sacharow S. Desmosterolosis presenting with multiple congenital anomalies. Eur J Med Genet. 2018 Mar;61(3):152-6.
Smith DW, Lemli L, Opitz JM. A newly recognized syndrome of multiple congenital anomalies. J Pediatr. 1964 Feb;64(2):210–7.
Nowaczyk MJM, Wassif CA. Smith-Lemli-Opitz Syndrome. In: GeneReviews®. University of Washington, Seattle, Seattle (WA);1993. [Updated 2020 Jan 30].
Eroglu Y, Nguyen-Driver M, Steiner RD, et al. Normal IQ is possible in Smith-Lemli-Opitz syndrome. Am J Med Genet Part A. 2017 Aug;173(8):2097–100.
Bianconi SE, Cross JL, Wassif CA, Porter FD. Pathogenesis, Epidemiology, Diagnosis and Clinical Aspects of Smith-Lemli-Opitz Syndrome. Expert Opin orphan drugs. 2015 Mar;3(3):267-80.
Lee RW, Conley SK, Gropman A, Porter FD, Baker EH. Brain magnetic resonance imaging findings in Smith-Lemli-Opitz syndrome. Am J Med Genet A. 2013 Oct;161A(10):2407-19.
Rojare C, Opdenakker Y, Laborde A, Nicot R, Mention K, Ferri J. The Smith–Lemli–Opitz syndrome and dentofacial anomalies diagnostic: Case reports and literature review. Int Orthod. 2019 Jun;17(2):375–83.
Lee RW, McGready J, Conley SK, Yanjanin NM, Nowaczyk MJ, Porter FD. Growth charts for individuals with Smith-Lemli-Opitz syndrome. Am J Med Genet A. 2012 Nov;158A(11):2707-13.
Prosnitz AR, Leopold J, Irons M, Jenkins K, Roberts AE. Pulmonary vein stenosis in patients with Smith-Lemli-Opitz syndrome. Congenit Heart Dis. 2017 Jul;12(4):475–83.
Wassif CA, Kratz L, Sparks SE, et al. A Placebo-Controlled Trial of Simvastatin Therapy in Smith-Lemli-Opitz Syndrome. Genet Med]. 2017 Mar;19(3):297-305.
